TENDER: ONASEMNOGENE ABEPARVOVEC INTRAVENEOUS (ZOLGENSMA®) SERVICE & ONASEMNOGENE ABEPARVOVEC INTRATHECAL (OAV101 IT) SERVICE | NHS ENGLAND
TENDER ONASEMNOGENE ABEPARVOVEC INTRAVENEOUS (ZOLGENSMA®) SERVICE & ONASEMNOGENE ABEPARVOVEC INTRATHECAL (OAV101 IT) SERVICE NHS ENGLAND
Reference
2026/S 000-053026
Description
Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered…
Total value (estimated)
- £26,136,000 excluding VAT
Contract dates (estimated)
- Submission deadline: 8 July 2026, 12:00pm
Main procurement category
Services
Contract locations
- UK – United Kingdom
Contracting authority
NHS England
United Kingdom